Characterization and validation of a streptozotocin-induced diabetes model in the vervet monkey

Journal of Pharmacological and Toxicological Methods

Volumn 63, Issue 3, 2011, Pages 296-303

  Kavanagh, Kylie ^a   Flynn, David M ^a   Nelson, Chris ^a   Zhang, Li ^a   Wagner, Janice D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Insulin; Methods; Monkey; Streptozotocin; Vervet

Indexed keywords

ALKALINE PHOSPHATASE; ARGININE; CREATININE; GLUCOSE; NITROGEN; STREPTOZOCIN; UREA;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CHLOROCEBUS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; ERYTHROCYTE VOLUME; EXPERIMENTAL MODEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET BETA CELL; UREA NITROGEN BLOOD LEVEL; VALIDATION PROCESS;

ANIMALS; ARGININE; BLOOD GLUCOSE; BODY WEIGHT; CERCOPITHECUS AETHIOPS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; STREPTOZOCIN;

CERCOPITHECUS; CERCOPITHECUS AETHIOPS; PRIMATES;

EID: 79954603467     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.02.003     Document Type: Article

References (36)

1. Bullock B.C., Lehner N.D.M., Clarkson T.B., Feldner M.A., Wagner W.D., Lofland H.B. Comparative primate atherosclerosis: I. Tissue cholesterol concentration and pathologic anatomy. Experimental and Molecular Pathology 1975, 22:151-175.
2. Cohen J.I., Davenport D.S., Stewart J.A., Deitchman S., Hilliard J.K., Chapman L.E. Recommendations for prevention of and therapy for exposure to b virus (cercopithecine herpesvirus 1). Clinical Infectious Diseases 2002, 35:1191-1203.
3. Dahlquist G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 2006, 49:20-24.
4. Ericzon B.G., Wijnen R.M., Kubota K., vd Bogaard A., Kootstra G. Diabetes induction and pancreatic transplantation in the cynomolgus monkey: Methodological considerations. Transplant International 1991, 4:103-109.
5. Gaur L.K. Nonhuman primate models for islet transplantation in type 1 diabetes research. ILAR Journal 2004, 45:324-333.
6. Gaur L.K., Nepom G.T., Lernmark A. Low-dose streptozotocin induces sustained hyperglycemia in Macaca nemestrina. Autoimmunity 2001, 33:103-114.
7. Hall-Craggs M., Brenner D.E., Vigorito R.D., Sutherland J.C. Acute renal failure and renal tubular squamous metaplasia following treatment with streptozotocin. Human Pathology 1982, 13:597-601.
8. Hayden M.R., Karuparthi P.R., Manrique C.M., Lastra G., Habibi J., Sowers J.R. Longitudinal ultrastructure study of islet amyloid in the hip rat model of type 2 diabetes mellitus. Experimental Biology and Medicine (Maywood) 2007, 232:772-779.
9. Howard C.F. Nonhuman primates as models for the study of human diabetes mellitus. Diabetes 1982, 31(Suppl. 1):37-42.
10. Hsueh W., Abel E.D., Breslow J.L., Maeda N., Davis R.C., Fisher E.A., et al. Recipes for creating animal models of diabetic cardiovascular disease. Circulation Research 2007, 100:1415-1427.
11. Jain S.K. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. The Journal of Biological Chemistry 1989, 264:21340-21345.
12. Jain S.K., McVie R., Smith T. Vitamin e supplementation restores glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic children. Diabetes Care 2000, 23:1389-1394.
13. Jonasson O., Jones C.W., Bauman A., John E., Manaligod J., Tso M.O. The pathophysiology of experimental insulin-deficient diabetes in the monkey. Implications for pancreatic transplantation. Annals of Surgery 1985, 201:27-39.
14. Koulmanda M., Qipo A., Chebrolu S., O'Neil J., Auchincloss H., Smith R.N. The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascilularis). American Journal of Transplantation 2003, 3:267-272.
15. Kume E., Aruga C., Takahashi K., Miwa S., Dekura E., Itoh M., et al. Morphological and gene expression analysis in mouse primary cultured hepatocytes exposed to streptozotocin. Experimental and Toxicologic Pathology 2005, 56:245-253.
16. Kume E., Fujimura H., Matsuki N., Ito M., Aruga C., Toriumi W., et al. Hepatic changes in the acute phase of streptozotocin (sz)-induced diabetes in mice. Experimental and Toxicologic Pathology 2004, 55:467-480.
17. Larsen M.O., Rolin B., Sturis J., Wilken M., Carr R.D., Porksen N., et al. Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Gottingen minipigs in vivo. American Journal of Physiology. Endocrinology and Metabolism 2006, 290:E670-E677.
18. Levine B.S., Henry M.C., Port C.D., Rosen E. Toxicologic evaluation of streptozotocin (NSC 85998) in mice, dogs and monkeys. Drug and Chemical Toxicology 1980, 3:201-212.
19. Litwak K.N., Cefalu W.T., Wagner J.D. Chronic hyperglycemia increases arterial low-density lipoprotein metabolism and atherosclerosis in cynomolgus monkeys. Metabolism 1998, 47:947-954.
20. Litwak K.N., Cefalu W.T., Wagner J.D. Streptozotocin-induced diabetes mellitus in cynomolgus monkeys: Changes in carbohydrate metabolism, skin glycation, and pancreatic islets. Laboratory Animal Science 1998, 48:172-178.
21. Matveyenko A.V., Veldhuis J.D., Butler P.C. Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 2006, 55:2347-2356.
22. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the united states, 1999-2004. JAMA 2006, 295:1549-1555.
23. Pitkin R.M., Reynolds W.A. Diabetogenic effects of streptozotocin in rhesus monkeys. Diabetes 1970, 19:85-90.
24. Rood P.P., Bottino R., Balamurugan A.N., Smetanka C., Ezzelarab M., Busch J., et al. Induction of diabetes in cynomolgus monkeys with high-dose streptozotocin: Adverse effects and early responses. Pancreas 2006, 33:287-292.
25. Rudel L.L., Bond M.G., Bullock B.C. LDL heterogeneity and atherosclerosis in nonhuman primates. Annals of the New York Academy of Sciences 1985, 454:248-253.
26. Sato H., Arikawa J., Furuya M., Kitoh J., Mannen K., Nishimune Y., et al. Prevalence of herpes B virus antibody in nonhuman primates reared at the National University of Japan. Experimental Animals 1998, 47:199-202.
27. Takimoto G., Jones C., Lands W., Bauman A., Jeffrey J., Jonasson O. Biochemical changes in rhesus monkey during the first days after streptozotocin administration are indicative of selective beta cell destruction. Metabolism 1988, 37:364-370.
28. Tal M.G., Hirshberg B., Neeman Z., Bunnell D., Soleimanpour S., Bacher J., et al. Induction of diabetes in nonhuman primates by means of temporary arterial embolization and selective arterial injection of streptozotocin. Radiology 2004, 230:163-168.
29. Theriault B.R., Thistlethwaite J.R., Levisetti M.G., Wardrip C.L., Szot G., Bruce D.S., et al. Induction, maintenance, and reversal of streptozotocin-induced insulin-dependent diabetes mellitus in the juvenile cynomolgus monkey (Macaca fascilularis). Transplantation 1999, 68:331-337.
30. VandeBerg J.L., Williams-Blangero S. Advantages and limitations of nonhuman primates as animal models in genetic research on complex diseases. Journal of Medical Primatology 1997, 26:113-119.
31. Virtue M.A., Furne J.K., Nuttall F.Q., Levitt M.D. Relationship between ghb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 2004, 27:931-935.
32. Wagner J.D., Cline J.M., Shadoan M.K., Bullock B.C., Rankin S.E., Cefalu W.T. Naturally occurring and experimental diabetes in cynomolgus monkeys: A comparison of carbohydrate and lipid metabolism and islet pathology. Toxicologic Pathology 2001, 29:142-148.
33. Weigler B.J., Roberts J.A., Hird D.W., Lerche N.W., Hilliard J.K. A cross sectional survey for b virus antibody in a colony of group housed rhesus macaques. Laboratory Animal Science 1990, 40:257-261.
34. White J.A., Bolstridge M.C., Downing H.J., Helm E.H., Klomfass H.J. Diabetogenic drugs in the vervet monkey. South African Medical Journal 1974, 48:273-276.
35. Whitley R.J., Hilliard J.K. Cercopithecine herpesvirus 1 (B virus). Fields virology 2001, 2835-2848. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
36. Wijkstrom M., Kirchhof N., Graham M., Ingulli E., Colvin R.B., Christians U., et al. Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology 2005, 207:117-127.